While Large/Mid Cap Biotechnology companies are boasting rising profitability, better cash flows, and stronger drug pipelines, the Small/Micro Cap Biotech firms, in general, have little tangible to show and valuations may be above the comfort zone.
May
08
2015
Small Cap Biotech Valuations: Proceed With Caution
Login
For full access, please enter your credentials.
Not a Subscriber?
If you are interested in subscribing to The Leuthold Group, contact us online or give us a call at 612-332-1567.
Contact UsAbout The Author
Perception for the Professional
July 2025 Issue
Featured Articles
Sector Navigator
July 2025 Issue
Recent Tags
Selloff
(1)
Recession
(70)
Growth
(120)
Value
(132)
Germany
(4)
Dreams and Nightmares
(5)
Yield Curve
(86)
Election
(11)
China
(45)
Dollar
(56)
Gold
(84)
Easing
(1)
Market Rotation
(2)
CPI
(171)
Inflation
(585)
Factor Performance
(18)
Japan
(48)
Yen
(7)
Wealth Effect
(9)
Bank Lending
(1)